Management of Rheumatic Heart Disease

Introduction to Rheumatic Heart Disease Management

The American College of Cardiology and European Heart Journal recommend a multi-level approach including secondary prophylaxis with antibiotics, medical management of cardiac complications, and timely intervention for valve disease to reduce morbidity and mortality in patients with rheumatic heart disease 1, 2

The American College of Cardiology recommends intramuscular benzathine penicillin G (1.2 million units every 4 weeks) as the first-line antibiotic prophylaxis regimen with the strongest evidence for preventing recurrences in patients with rheumatic heart disease 3, 4
For penicillin-allergic patients, the American College of Cardiology suggests alternatives including oral penicillin V, sulfadiazine, or macrolide antibiotics 5, 4
The duration of prophylaxis depends on the severity of the disease, with 10 years after last attack or until age 40 recommended for patients with persistent valvular disease, and 10 years after last attack or until age 21 for those with rheumatic fever and carditis but no residual heart disease 4

The American College of Cardiology recommends standard guideline-directed medical therapy for left ventricular systolic dysfunction, including diuretics, ACE inhibitors or ARBs, beta-blockers, aldosterone antagonists, and sacubitril/valsartan when indicated, for patients with rheumatic heart disease and heart failure 4, 6, 7
The European Heart Journal suggests careful blood pressure management, avoiding abrupt BP lowering in stenotic lesions, and anticoagulation for stroke prevention in patients with atrial fibrillation 6

The European Heart Journal recommends percutaneous or surgical intervention for moderate-severe mitral stenosis with symptoms, asymptomatic patients with severe rheumatic mitral stenosis before pregnancy, and valve replacement surgery when percutaneous mitral balloon commissurotomy is contraindicated or unsuccessful 6

The European Heart Journal suggests that women with moderate-severe rheumatic heart disease should be evaluated before pregnancy and interventional therapy considered, and that medical management during pregnancy includes beta-blockers, diuretics, and anticoagulation as needed 2, 6

The American College of Cardiology recommends antibiotic prophylaxis before dental procedures involving manipulation of gingival tissue, periapical region of teeth, or perforation of oral mucosa in patients with rheumatic heart disease, unless they are already on secondary prevention antibiotics 3, 6

The American College of Cardiology suggests optimal oral health maintenance, influenza and pneumococcal vaccinations, and regular echocardiographic monitoring every 3-5 years for mild disease, every 1-2 years for moderate disease, and every 6-12 months for severe disease or when left ventricle is dilating 5, 4, 6, 7

The Nature Reviews Cardiology recommends register-based comprehensive rheumatic heart disease control programs, community health worker involvement, health education for patients and families, and integration of rheumatic heart disease control into primary health care systems 1, 8

The American College of Cardiology and European Heart Journal warn against discontinuing secondary prophylaxis too early, inadequate anticoagulation monitoring, failure to recognize pregnancy as a high-risk period, neglecting regular follow-up echocardiography, and overlooking the need for infective endocarditis prophylaxis during high-risk procedures 1, 3, 4, 6, 7

The American College of Cardiology recommends evaluating all patients with symptomatic severe rheumatic mitral stenosis (mitral valve area ≤1.5 cm²) for percutaneous mitral balloon commissurotomy (PMBC) or mitral valve surgery within 3 months of diagnosis 9
PMBC is preferred for patients with favorable valve morphology (mobile, relatively thin leaflets free of calcium, without significant subvalvular fusion) and less than 2+ mitral regurgitation in the absence of left atrial thrombus 9
Surgical intervention is indicated when valve anatomy is unfavorable, PMBC has failed, or patients have moderate-to-severe tricuspid regurgitation requiring repair 9
Long-term outcomes show that 70-80% of patients with good initial PMBC results remain free of recurrent symptoms at 10 years 9
The American College of Cardiology advises against delaying valve intervention in symptomatic patients with severe disease, as medical therapy alone is not a substitute for definitive treatment 9